Skip to main content

Published locations for First SGLT1/2 inhibitor shows ‘spectacular’ phase 3 safety and efficacy in T2D

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. First SGLT1/2 inhibitor shows ‘spectacular’ phase 3 safety and efficacy in T2D

User login

  • Reset your password
  • /content/first-sglt1/2-inhibitor-shows-spectacular-phase-3-safety-and-efficacy-t2d
  • /emed-journal/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3-safety
  • /familypracticenews/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3
  • /fedprac/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3-safety-and
  • /internalmedicinenews/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3
  • /clinicalendocrinologynews/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular
  • /ecardiologynews/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3
  • /cardiology/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3-safety-and
  • /endocrinology/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3-safety
  • /internalmedicine/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3
  • /familymedicine/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3-safety
  • /emergencymedicine/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3
  • /type-2-diabetes-icymi/article/232044/heart-failure/first-sglt1/2-inhibitor-shows-spectacular-phase-3